Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
Related Articles
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Biospace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial…July 12, 2022
Anumana Named to Fierce Medtech’s 2022 Fierce 15
AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac careMarch 20, 2023
How Doctors Use AI to Help Diagnose Patients
Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially…February 28, 2023
Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for…July 06, 2022